nevsky-spb.ru


Atyr Pharma Stock Forecast

Research aTyr Pharma's (Nasdaq:LIFE) stock price, latest news & stock analysis. Find everything from its Valuation, Future Growth, Past Performance and. Bid Price and Ask Price. The bid & ask refers to the price that an investor is willing to buy or sell a stock. The bid is the highest amount that. The company's average rating score is , and is based on 2 buy ratings, 1 hold rating, and no sell ratings. Price Target Upside/Downside. According to. aTyr Pharma Inc. analyst ratings, historical stock prices, earnings estimates & actuals. LIFE updated stock price target summary. LIFE | Complete aTyr Pharma Inc. stock news by MarketWatch. View real-time stock prices and stock quotes for a full financial overview.

Discover aTyr Pharma's earnings and revenue growth rates, forecasts, and the latest analyst predictions while comparing them to its industry peers. The average one-year price target for aTyr Pharma, Inc. is $ The forecasts range from a low of $ to a high of $ A stock's price target is. According to the current price, aTyr Pharma is % away from the week high. What are analysts forecasts for aTyr Pharma stock? The 16 analysts offering. Atyr Pharma Stock Forecast, LIFE stock price prediction. Price target in 14 days: USD. The best long-term & short-term Atyr Pharma share price. Zacks' proprietary data indicates that aTyr Pharma, Inc. is currently rated as a Zacks Rank 3 and we are expecting an inline return from the LIFE shares. aTyr Pharma (LIFE) Stock Forecast & Price Prediction , According to our current LIFE stock forecast, the value of aTyr Pharma shares will drop by -. During the last trading day the stock fluctuated % from a day low at $ to a day high of $ The price has fallen in 6 of the last 10 days and is down. According to analysts, aTyr Pharma's stock has a predicted upside of 1,% based on their month stock forecasts. What analysts cover aTyr Pharma? aTyr. The volatility of relative hype elasticity to ATyr Pharma is about %. The volatility of related hype on ATyr Pharma is about % with expected price.

LIFE - aTyr Pharma - Stock Forecast LIFE is currently covered by 4 analysts with an average price target of $ This is a potential upside of $ ( aTyr Pharma, Inc. ; Price Momentum. LIFE is trading in the middle ; Price change. The price of LIFE shares has decreased $ ; Closed at $ The stock has. The Wall Street analyst predicted that Atyr Pharma's share price could reach $ by Feb 21, The average Atyr Pharma stock price prediction forecasts a. Get aTyr Pharma Inc (LIFE:NASDAQ) real-time stock quotes, news, price and financial information from CNBC. The 3 analysts with month price forecasts for aTyr Pharma stock have an average target of , with a low estimate of 19 and a high estimate of The. aTyr Pharma Inc. ; Open. $ Previous Close ; YTD Change. %. 12 Month Change. % ; Day Range · 52 Wk Range - aTyr Pharma (LIFE) has a Smart Score of 6 based on an analysis of 8 unique data sets, including Analyst Recommendations, Crowd Wisdom, and Hedge Fund. Based on analysts offering 12 month price targets for LIFE in the last 3 months. The average price target is $ with a high estimate of $ and a low. Based on short-term price targets offered by three analysts, the average price target for Atyr Pharma comes to $ The forecasts range from a low of $

LIFE Price · $ ; Market Cap · $M ; 52 Week Low · $ ; 52 Week High · $ ; P/E · x. aTyr Pharma's Market Cap Drops To US$66m Leaving Insiders With Losses. Insiders who bought US$k worth of aTyr Pharma, Inc.'s (NASDAQ:LIFE) stock at an. The forecasts range from a low of $ to a high of $ A stock's price target is the price at which analysts consider it fairly valued with respect to. aTyr Pharma Announces Fourth Quarter and Full Year Results and Provides Corporate Update. Phase 3 EFZO-FIT™ study of efzofitimod in patients with pulmonary. aTyr Pharma, Inc. (nevsky-spb.ru): Stock quote, stock chart, quotes, analysis, advice, financials and news for Stock aTyr Pharma, Inc. | Nasdaq: LIFE.

rytm | rocky dinar

10 11 12 13 14


Copyright 2012-2024 Privice Policy Contacts SiteMap RSS